COO: Steve Holmes

Advent Contact: Raj Parekh

Development of antibodies to the next generation of therapeutic targets

Capella is an early-stage, preclinical, antibody discovery company that has identified a number of inflammatory and oncology targets against which it is developing novel antibodies.

Advent founded Capella in 2014. Capella completed a £10.5M Series A financing in 2015.